23+ Abt-263 (Navitoclax). Independence model, and more than 50% of the ovarian cell lines exhibited strong synergy for the navitoclax/paclitaxel. This phase i study (nct01009073) evaluated the safety.
Independence model, and more than 50% of the ovarian cell lines exhibited strong synergy for the navitoclax/paclitaxel. This compound inhibits the growth of. This phase i study (nct01009073) evaluated the safety.
Independence model, and more than 50% of the ovarian cell lines exhibited strong synergy for the navitoclax/paclitaxel.
This compound inhibits the growth of. This phase i study (nct01009073) evaluated the safety. Independence model, and more than 50% of the ovarian cell lines exhibited strong synergy for the navitoclax/paclitaxel. This compound inhibits the growth of.